A cancer genomic report may identify a mutation, but that does not automatically mean a matching targeted therapy is available.
Our latest article explains the difference between a detected alteration, an oncogenic variant, and an actionable biomarker. It also examines why the exact variant, tumor type, evidence level, previous treatments, and the patient’s current health must all be considered before a molecular finding can influence treatment discussions.
For international patients exploring specialist opinions or Medical Tourism China, MedBridgeNZ can coordinate medical-record translation, case preparation, specialist access, and travel logistics. MedBridgeNZ is a medical concierge provider and does not provide diagnosis, treatment, or direct medical advice.
Read the full article: Cancer Mutation and Targeted Therapy: Is There a Drug?
